Ruxolitinib Cream Is Tolerable and Effective in Cutaneous GVHD
A cream formulation of ruxolitinib was deemed safe and effective compared with placebo in patients with cutaneous graft-versus-host disease.
Source: onclive.com
Dermtech Smart News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Dermtech Smart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Dermtech Smart Today - Breaking & Trending Today
DermTech : Pledges up to $1 Million to Raise Awareness and Support Accessibility of Skin Exams
™ Campaign to Join the Pledge to Stop Melanoma Deaths In honor of Melanoma and Skin Cancer Awareness Month, DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by the non-invasive DermTech Smart Sticker ™ platform and its melanoma test, the Pigmented Lesion Assay or PLA, is launching the #Stickit2Melanoma campaign, urging the public to get proactive about skin exams. One in five Americans develop skin cancer by the age of 70, and every hour of every day one American dies from melanoma. It is not only one of the most common cancers diagnosed in the U.S...
Source: marketscreener.com